End of the Clopidogrel days ? New Drug Prasugrel

• Evidence suggests that the oral antiplatelet agent prasugrel will be an important addition to the long term management of patients who have sustained an acute non-ST elevation myocardial infarction.Better action with comparable side effect profile
  

• Compared to clopidogrel, death rates after a first ischemic event and recurrent events are less with prasugrel .

• Furthermore, prasugrel effectively suppressed platelet activity in a larger numbers of patients than clopidogrel, since 20 to 25 percent of patients appeared to be clopidogrel-resistant.